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Osteoporosis is deﬁned as a progressive systemic skeletal disease characterized by low bone mass and microarchitectural
deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Although bone mass and
quality is mainly determined genetically, many other factors, including lifestyle and nutrition also have an impact on bone health.
It has been suggested that dietary protein intake may be a risk factor for osteoporosis, and high-protein diets are associated with
increased bone loss. Many scientists have examined the relationship between types of protein and urinary calcium excretion, and
foundthatalthoughanimalproteinwasassociatedwithincreasedurinarycalciumexcretion,soyproteinwasnot.Thereissuﬃcient
evidence suggesting soy isoﬂavones may have potential beneﬁts for bone. Soy protein with naturally occurring phytoestrogens,
mainly isoﬂavones protect against bone loss and synthetic soy ipriﬂavone in some studies has been shown to favorably aﬀect, but
a cause and eﬀect relationship has not been established between the consumption of ipriﬂavone and maintenance of bone mineral
density in post-menopausal women. Therefore it is too early to recommend it as a supplement for this group of women.
1.Introduction
Osteoporosis is a skeletal disorder characterized by compro-
mised bone strength, a disorder that predisposes to fractures
resultingfromnoidentiﬁableinjuryorfromminimaltrauma
insuﬃcient to fracture normal bone. Bone strength is the
result of two major determinants: bone mineral content and
bone quality. A person’s bone mineral content is a function
of the interaction of two key factors: the uppermost amount
of bone achieved during youth (called the peak bone mass,
PBM) in combination with the rate of subsequent bone loss.
Growth in bone size and strength occurs during childhood,
through adolescence and is usually completed in the 20s.
After peak bone mass is achieved during the third
decade of life, bone architecture is maintained by a constant
remodeling process. Osteoclasts attach to a speciﬁc area of
bone, remove old bone (resorption pit), then osteoblasts
move in and ﬁll this pit with new bone. The balance
between these processes shifts at menopause [1]a n dw o m e n
typically undergo a rapid phase of bone loss that begins
approximately2to3yearsbeforethecessationofmensesand
continues for up to 5 years postmenopause [2]. Although the
decreased concentrations of circulating estrogen observed
during menopause and the rapid phase of bone loss are
chieﬂy responsible for the process [2], many other factors
are associated with increased fracture risk [3]. These factors
includepriorfragilityfracture,advancedage,afamilyhistory
of osteoporotic fracture, and the use of certain medications
[1]. Additional predictors of bone loss and fracture risk
in early postmenopause include prolonged low vitamin D
and calcium intake and low body weight as well as high
consumption of animal protein, inadequate intake of plant
protein, soybean isoﬂavones and n-3 PUFA [1, 4].
Although hormone replacement therapy (HRT) is able
to ameliorate the loss of estrogen at menopause and thus
address the concerns related to osteoporosis, there remains
substantial interest in alternatives, particularly dietary alter-
natives, to HRT. It is in this regard that phytoestrogens have
received considerable interest in relation to bone health.
Related to isoﬂavones in particular is research showing that
ipriﬂavone, a synthetic isoﬂavone, eﬀectively reduces bone
loss in postmenopausal women [5]. Interest in the potential2 Journal of Osteoporosis
relation between phytoestrogens and osteoporosis risk was
generated from observations of signiﬁcantly lower numbers
of hip fractures in Asian women, relative to Caucasian
women [6]. Numerous observational studies relating soy
intake of pre- and postmenopausal women to BMD have
generally reported signiﬁcant positive associations [7], with
only some studies reporting no association [8]. Some studies
assessing BMD have found positive eﬀects of soy and
soy isoﬂavones speciﬁcally on BMD of the lumbar spine
[8]. Studies assessing biomarkers of bone formation and
resorption have been less consistent, with some reporting
beneﬁcial eﬀects with respect to bone health [9] while others
have reported no signiﬁcant eﬀects [10]o re ﬀects too small
to be of clinical relevance [11].
Selective estrogen receptor modulators (SERMs), for
example, raloxiﬁne have been shown to be eﬀective in
preventing bone loss or increasing bone mass. SERMs are
a group of chemically diverse non-steroidal compounds
that bind to and interact with the estrogen receptors. Soy
isoﬂavones, have been characterized as naturally occurring
SERMs with similar beneﬁcial eﬀects to raloxifene on bone
without its side eﬀects [12]. This paper focuses on the role
of soy protein and soy phytoestrogens, especially, isoﬂavones
as well as the synthetic isoﬂavone—ipriﬂavone on the
prevention and management of osteoporosis.
2. Dietary Sources of Isoﬂavonoids and
TheirBiopotency
Isoﬂavonoids from legumes, including genistein 2 and
daidzein,arethemoststudiedphytoestrogens.Theycanexist
as glucosides or as aglycones, the glucosides being readily
hydrolyzed in the gut to their aglycones. The aglycones
are easily transported across intestinal epithelial cells [13].
Although isoﬂavones are non-steroidal compounds, they are
structurally similar to naturally occurring estrogens, syn-
thetic estrogens and anti-estrogens. The structural similarity
of phytoestrogens to endogenous estrogens has prompted
the hypothesis that phytoestrogens exert hormonal or anti-
hormonal eﬀects relevant to the risk of hormone-dependent
disease and/or their suitability as a dietary alternative to
hormone replacement therapy.
Isoﬂavones are found in highest amounts in soybeans
and soy foods, although they are also present in other
beans and legumes. Soy foods generally contain 1.2–3.3mg
isoﬂavones/g dry weight, with the precise amount depending
on numerous factors, including the type of soy food [14, 15]
as well as soybean variety, harvest year and geographical
location [14, 15]. Table 1 below shows the dietary sources of
isoﬂavones.
Studies have estimated typical isoﬂavone intakes to be
30–50mg/day for Asians [14, 15] and less than 1mg/day for
postmenopausal women living in the USA [16]. The plasma
concentrations of genistein 2 have been found to range from
0.1–10mM in the Asian population [17].
The major isoﬂavones present in soy foods include
genistein and daidzein and, to a lesser extent, glycitein.
Genisteinanddaidzeinarederivedfromgenistinanddaidzin
Table 1: Isoﬂavonoid content of selected legumes and soy-based
foods [16].
Food Genistein 2
(mg/100g)
Daidzein
(mg/100g)
Total
isoﬂavonoids
(mg/100g)∗
Soy-based
infant formula 1.6–15 0.8–9.7 2.6–31
Soy milk 1.1–11.3 1.1–9.8 1.3–21
Soybeans,
mature 1.1–150 0.5–91 1.7–221
Tofu 5.0–42.1 0.6–25.6 3.6–67.5
Beans 0.007–0.5 0.008–0.04 0.015–0.5
Chick peas 0.07–0.2 0.01–0.2 1.1–3.6
∗Including formomonetin and biochanin.
astheresultoftheactionofgutmicroﬂora.Theyoccurinsoy
conjugated to sugar moieties as glycosides, termed genistin,
daidzinandglycitin.Genistein2hasone-thirdthepotencyof
estradiol 1 when it interacts with estrogen receptor-β (ERβ),
and one thousandth of the potency of estradiol 1 when it
interacts with ERα. Genistein 2 can induce similar responses
in breast, ovarian, endometrial, prostate, vascular, and bone
tissues and cell lines as estradiol 1 [18, 19].
Although fermentation of soy can reduce the amount of
isoﬂavonoids present by a factor of 2-3 [15, 16], bioavail-
ability of isoﬂavonoids is higher in fermented products, so
urinary excretion rates are similar for people consuming
fermentedandunfermentedproducts.Eventhoughgenistein
2 has relatively low potency compared to estradiol 1, high
concentrations in plasma may be suﬃcient to cause a variety
of physiological eﬀects.
3.Bone-Modulating Effects of Soy Proteinand
Soy Isoﬂavones
Estrogen plays an important role in maintaining bone
density by regulating the formation and resorption of bone
[20]. Since lower circulating estradiol-1 levels are found
during menopause, calcium is lost from the bone into blood
plasma, leading to osteoporosis [21]. One of the aims of
hormone replacement therapy (HRT) is to prevent or lower
the incidence of osteoporosis in postmenopausal women.
Prior to the turn of the twentieth century it was assumed
that estrogens were exclusively produced by animals. How-
ever, the principle that plants can also produce estrogen-
like molecules was established by 1966 [22]. Now, it is
recognized that certain plants and plant products contain
phytoestrogens. One group of such compounds reported to
have estrogenic activity is the ﬂavonoids [23, 24].
Flavonoids are a large chemical class that are formed
through the phenylpropanoid-acetate biodemial pathway
via chalcone synthase and condensation reactions with
malonyl CoA. Isoﬂavonoids are a subclass of ﬂavonoids,
where one phenolic ring has migrated from C-3 to C-2.
The isoﬂavonoids from legumes, including genistein 2 and
daidzein,arethemoststudiedphytoestrogens.TheycanexistJournal of Osteoporosis 3
as glucosides or as aglycones, the glucosides being readily
hydrolyzed in the gut to their aglycones. The aglycones
are easily transported across intestinal epithelial cells [13].
Genistein 2 has one-third the potency of estradiol 1 when
it interacts with ERβ, and one thousandth of the potency
of estradiol 1 when it interacts with ERβ as determined by
expression of luciferase reporter gene construct in kidney
cells that had been cotransfected with ERα and ERβ [25].
Genistein 2 can induce similar responses in breast, ovarian,
endometrial, prostate, vascular, and bone tissues and cell
linesasestradiol-1[19,26].Genistein2canactasanestrogen
antagonist in some tissues.
Soy isoﬂavones have an inﬂuence not only on sex hor-
mone metabolism, but also possess other biological activities
including cholesterol-lowering properties, anti-carcinogenic
eﬀects and more recently their protective role in bone health
[27, 28].
Results of many studies on the protective role of soy
protein, its isoﬂavones, or their combination on bone
in ovarian hormone deﬁcient models of osteoporosis are
inconsistent. In these studies, the rate of bone formation
and bone resorption, as assessed by biochemical markers are
unchanged, decreased, or increased. Analogous to animal
ﬁndings, the eﬀect of soy and its isoﬂavones on bone in
humans are also conﬂicting. Furthermore, it is not clear
whether the bone protective eﬀect of soy protein is due to
its amino acid composition [29], nonprotein constituents
suchasisoﬂavones[30,31],oracombinationofthesefactors
[31].Animalstudiesusingtheovariectomizedratmodelper-
formed by Arjmandi et al. [30] showed that the soy diet with
isoﬂavones was more eﬀective in preventing ovariectomy-
induced loss of bone density than either the casein or the soy
protein, depleted of its isoﬂavones, diet. Using an osteopenic
ratmodel,Arjmandietal.[31]demonstratedaslightreversal
of the ovarian hormone deﬁciency-inducedloss of bone with
soy protein diets with either normal or reduced isoaﬂvone
content. Although animal ﬁndings [30, 31], so far, indicate
theimportanceofisoﬂavonesinpreservingbone,itisstillnot
clear whether isoﬂavones can exert similar bone protective
eﬀects independently of soy protein.
Findings by Picherit et al. [32] support the bone
protective role of isoﬂavones independent of soy protein.
These authors reported that isoﬂavones dose-dependently
prevented ovariectomy-induced bone loss in a rat model.
However,thesamegroupofinvestigatorsdidnotﬁndsimilar
beneﬁcial eﬀects of isoﬂavones in reversing bone loss in
ovariectomized osteopenic rats [33], even though the rate
of bone turnover was reduced. Hence, one can speculate
that a longer treatment period with isoﬂavones would have
reversed bone loss. Whether the magnitude of eﬀects of
isoﬂavones on bone in these animal studies by Picherit
[32, 33] would have been greater had isoﬂavones been given
in conjunction with soy protein still remains to be answered?
On the other hand, studies investigating the eﬀects of
individual soy isoﬂavones, genistin and daidzin, support the
important role of these naturally occurring compounds in
bone health regardless of the dietary protein source. For
instance,twoweeksofagenistin-richtreatment(1.0mg/day)
in lactating ovariectomized rats was eﬀective in maintaining
trabecular bone tissue in comparison with ovariectomized
control animals [34]. Furthermore, in the same report,
genistin stimulated alkaline phosphatase activity of an
osteoblast-like cell line, suggesting a positive eﬀect on bone
formation. In another study, Fanti et al. [35] reported that
genistein (5mg/kg body weight) maintained both cortical
and trabecular bones in ovariectomized rats, and the bone-
sparing eﬀect of genistein appeared to be biphasic.
Although it is believed that genistin is the most potent of
all the soy isoﬂavones, study by Picherit et al. [36]r e p o r t e d
that daidzin, is more eﬃcient than genistin in preventing
the ovariectomy-induced increase in bone turnover and
decrease in bone mineral density. Clearly, this demonstrates
that there are uncertainties as to which isoﬂavone plays
a more important role in skeletal health. Use of a single
isoﬂavone may not necessarily be the approach to be taken
and future studies should address whether the combination
of isoﬂavones exerts a more pronounced eﬀect on bone.
To study the relation between soy isoﬂavone intake and
bone mineral density (BMD), Greendale et al. [37]a n a l y z e d
baseline data from the Study of Women’s Health Across
the Nation, a US community-based cohort study of women
aged42–52years.Their1996-1997analysisincludedAfrican-
American (n = 497), Caucasian (n = 1,003), Chinese (n =
200), and Japanese (n = 227) participants. Genistein and
daidzein intakes were highly correlated (r = 0.98); therefore,
analyses were conducted by using genistein. Median intakes
of genistein (measured in micrograms/day) by African
Americans and Caucasians were too low to pursue relational
analyses further. For Chinese and Japanese women, median
genistein intakes were 3,511 and 7,151μg/day, respectively.
Ethnic-speciﬁc, linear models were used to predict BMD as
a function of energy-adjusted tertile of intake, controlled
for relevant covariates. For Chinese women, no association
between genistein and BMD was found. Premenopausal, but
not perimenopausal, Japanese women whose intakes were
greater had higher spine and femoral neck BMD. Adjusted
mean spinal BMD of those in the highest tertile of intake
was 7.7% greater than that of women in the lowest tertile
(P = .02); femoral neck BMD was 12% greater in the highest
versus the lowest tertile (P<. 0001).
Most of the studies suggest that Phytoestrogens are
somewhat eﬀective in maintaining bone mineral density in
postmenopausal women [38, 39]. A double blind placebo
controlled study of postmenopausal women showed signif-
icant increase in BMD at the femoral neck after 12 months
of daily administration of 54mg genistein, isolated from
soy, although a signiﬁcant increase in osteocalcin and bone
speciﬁc alkaline phosphatase (BAP) was also observed [39].
In contrast 17β-estradiol 1 increased BMD with a signiﬁcant
decrease in osteocalcin and bone alkaline phospatase (BAP)
levels [39].
In a 24-week study comparing isoﬂavone rich soy protein
(80.4mg aglycone isoﬂavones/day) and isoﬂavone poor soy
protein(4.4mgaglyconeisoﬂavones/day)inperimenopausal
women, both BMD and bone mineral content (BMC) were
signiﬁcantly higher with the diet high in isoﬂavones [38].
There was no signiﬁcant change in the BMD or BMC of the
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high or low isoﬂavone soy protein diet; however, the woman
on the control diet had a signiﬁcant decrease of BMD and
BMC during this time. The women who had more bone
loss had higher BAP levels. Therefore BAP may be a better
indicator of bone turnover than bone formation [38].
The lumbar spine seems to beneﬁt the most from
consumption of soy phytoestrogens. A 24-week long study
with postmenopausal women consuming soy protein with
90mg isoﬂavones/day showed a signiﬁcant increase in BMD
of the lumbar spine, with no eﬀect on the femoral neck
or total body BMD [40]. There were no BMD eﬀects in
woman consuming soy protein with 56 mg isoﬂavones/day
[40]. The only study to examine the eﬀects of soy isoﬂavones
in premenopausal women showed no eﬀect on bone mineral
density levels [41], while signiﬁcant eﬀects were observed in
postmenopausal women in this study.
Brink et al. [42] carried out studies in healthy men
(59.2 ± 17.6y), who were assigned to consume 40g of
either SP or milk-based protein (MP) daily for 3mo in
a double-blind, randomized, controlled, parallel design.
Serum insulin-like growth factor-I (IGF-I), which is associ-
ated with higher rates of bone formation, was greater (P<
.01) in men supplemented with SP than in those consuming
MP. Serum alkaline phosphatase and bone-speciﬁc alkaline
phosphatase activities, markers of bone formation, and
urinary deoxypyridinoline excretion, a speciﬁc marker of
bone resorption, were not diﬀerent between the SP and MP
groups. Furthermore, because substantial reductions in bone
density occur in men at ∼65y of age, these authors analyzed
separately data for men ≥65y and those <65y of age. The
response to protein supplementation was consistent in the
two age groups. The eﬀects of SP on serum IGF-I levels
suggest that SP may positively inﬂuence bone in men. It
should however be mentioned that their study was short,
so longer-duration studies examining the eﬀects of SP or its
isoﬂavones on bone turnover and bone mineral density and
content in men are warranted.
There are studies showing that the consumption of
isoﬂavones has no any beneﬁts for women in early post-
menopausal period. Brink et al. [42]c o n d u c t e dar a n -
domized, double-blind, placebo-controlled, parallel, mul-
ticenter trial in two hundred thirty-seven healthy early
postmenopausal women (mean (±SD) age of 53 ± 3yand
time since last menses of 33 ± 15mo), who consumed
isoﬂavone-enriched foods providing a mean daily intake
of 110mg isoﬂavone aglycones or control products for 1y
while continuing their habitual diet and lifestyle. These
authors found that Consumption of isoﬂavone-enriched
products did not alter bone mineral density of the lumbar
spine and total body or markers of bone formation and
bone resorption. Furthermore, Hormone concentrations did
not diﬀer between the isoﬂavone and control groups. The
intake of isoﬂavone-enriched products resulted in increased
isoﬂavone concentrations in plasma and urine, whereas
control products did not.
A recent meta-analysis by Liu et al. [43] showed only
very slight beneﬁts of soy isoﬂavones in increasing BMD in
women. These authors identiﬁed 10 eligible RCTs in 896
women. A mean dose of 87mg soy isoﬂavones for at least
one year did not signiﬁcantly aﬀect BMD changes. The mean
(95% CI) diﬀerences in BMD changes (in mg/cm2/year)
were 4.1 (−1.6, 9.8) (0.4%) at the lumbar spine, −1.5
(−7.2, 4.3) (−0.3%) at the femoral neck under random-
eﬀects model, and 2.5 (−0.5, 5.4) (0.2%) at the total
hip by ﬁx-eﬀects model, respectively. Similar results were
obtained in subgroup analyses by isoﬂavone sources (soy
protein versus isoﬂavone extract), ethnic diﬀerences (Asian
versus Western). Larger dose (≥80mg/d), but not lower dose
(<80mg/d), of isoﬂavone intervention tended to have a weak
beneﬁcial eﬀect on spine BMD (P = .08 versus P = .94). Liu
et al. [43] concluded that soy isoﬂavone supplementation is
unlikely to have signiﬁcant favorable on BMD at the lumbar
spine and hip in women.
4. Isoﬂavones and Bone Health:
Mechanisms of Action
Soy isoﬂavones are natural products that could be used
as an alternative to menopausal hormone therapy because
they are structurally and functionally related to 17beta-
estradiol. Results of mechanistic studies indicate that soy or
its isoﬂavones, while suppressing the rate of bone resorption
concomitantly enhance the rate of bone formation. In
ovariectomized rats, soy isoﬂavones have been shown [32,
33] to reduce the urinary excretion of deoxypyridinoline
(Dpd), a speciﬁc marker of bone resorption. Similarly, at
leastthreehumanstudieshaveclearlydemonstratedtheanti-
resorptive properties of soy or its isoﬂavones. One of these
studies was a cross-sectional study by Horiuchi et al. [44],
in which soy protein intake in Japanese postmenopausal
women was associated with lower urinary Dpd excretion.
In the second study, postmenopausal women who were
assigned to a soy milk regimen, providing 60–70mg of
isoﬂavones, experienced a signiﬁcant decrease in urinary N-
terminal cross-linked peptide, another speciﬁc marker of
bone resorption [45]. Arjmandi et al. [46] reported that the
daily consumption of 40 g soy protein, but not milk protein,
for three months by postmenopausal women who were not
on HRT signiﬁcantly reduced the urinary excretion of Dpd.
Ma et al. [47]a n dC h o ie ta l .[ 48] carried out a
meta-analysis of nine studies with a total of 432 sub-
jects on the impact of isoﬂavone consumption on bone
markers. They found that urinary Dpd concentration in
subjects who consumed isoﬂavones decreased signiﬁcantly
by −2.08nmol/mmol (95% conﬁdence interval (CI): −3.82
to −0.34nmol/mmol) in comparison with that in subjects
who did not consume isoﬂavones. Isoﬂavone intake versus
placebo intake signiﬁcantly increased BAP by 1.48μg/L (95%
CI:0.22–2.75μg/L).DecreasesintheurinaryDpdconcentra-
tionwithisoﬂavoneintakeof<90mg/dayandwithtreatment
lasting less than 12 weeks were −2.34nmol/mmol (95% CI:
−4.46 to −0.22nmol/mmol) and −2.03nmol/mmol (95%
CI: −3.20 to −0.85nmol/mmol), respectively.
It is reasonable to suggest that soy or its isoﬂavones
enhance bone formation based on at least two lines of
evidence: (1) soy isoﬂavones stimulate osteoablastic activity
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or its isoﬂavones promote insulin-like growth factor-I (IGF-
I) production [31]. In a recent review, Atmaca [49] stated
that soy isoﬂavones act on both osteoblasts and osteoclasts
through genomic and nongenomic pathways. Using a rat
model of osteopenia, Arjmandi et al. [31] found that soy
protein increased the gene expression of IGF-I as indicated
by higher femoral mRNA levels. In that study, incorporation
of soy protein with normal isoﬂavone content (2.3mg/g pro-
tein) had a greater eﬀect on femoral IGF-I mRNA than the
isoﬂavone-depleted soy protein-based diet (approximately
0.1mg/g protein). This ﬁnding indicates that isoﬂavones
may have a role in enhancing the synthesis of IGF-I and
more importantly at the bone level. Similarly, Arjmandi
et al. [46] showed that soy protein supplementation also
signiﬁcantly increased serum IGF-I levels in humans. It is
well recognized that IGF-I enhances osteoblastic activity
in humans and IGF-I concentrations have been reported
to correlate positively with bone mass in pre- [50], peri-
[51], and post- [52] menopausal women. Nonetheless, these
indirect observations should be conﬁrmed using in vitro and
in vivo models including long-term human studies in which
more deﬁnitive techniques such as bone histology and bone
histomorphometry are assessed.
Ma et al. [53] carried out a meta-analysis of 10 random-
izedcontrolledtrials ontheinﬂuence ofsoy isoﬂavone intake
on spine bone mineral density (SBMD) in 608 menopausal
women and found that isoﬂavones contributed signiﬁcantly
to the increase of SBMD, especially in post-menopausal
women. They concluded that Intervention duration for 6
months may be enough for isoﬂavones to produce favorable
eﬀects on spinal bone and that the intake of isoﬂavone at
the level of >90mg/day may be better for protecting against
spinal bone loss.
5. Ipriﬂavone:The Synthetic Isoﬂavone and
Management of Osteoporosis
Ipriﬂavone (IP) is an isoﬂavone, synthesized from the soy
isoﬂavone, daidzein. Only a few studies have been conducted
with IP to determine its eﬃcacy in inhibiting the decrease
in BMD and only six intervention studies have been so far
carried out in humans on the eﬀects of IP on bone mass
and turnover [54–59]. Other papers related to ipriﬂavone
include a review of randomised controlled trials (RCTs) [60]
and a review on the mechanisms of action of iproﬂavone on
bone metabolism [61]. There has been so far only one large
multicentre RCT on the eﬀects of ipriﬂavone on BMD and
turnover in postmenopausal women [62].
Several in vitro studies suggest that ipriﬂavone (typically
200mg orally 3 times per day) may inhibit bone resorption
and increase bone formation, a mechanism by which ipri-
ﬂavone could prevent bone loss in postmenopausal women
[61]. Four of the human intervention studies provided
assessed the eﬀects of ipriﬂavone on BMD and biochemical
markers of bone turnover in patient populations with acute
leukemia [57], with stroke-induced hemiplegia [58], or with
pharmacologically-induced hypogonadism caused by the
administration a gonadotropin hormone-releasing hormone
agonist [54, 59]. It should be mentioned that evidence
on the beneﬁts of ipriﬂavone from these studies does not
establish that these patient populations are representative
of the general population with regard to bone status, or
that results obtained in studies on such patients relating
to the treatment of rapid bone loss can be extrapolated
to the maintenance of bone mineral density in the general
population of adults.
Three of the papers showing the beneﬁts of ipriﬂavone
report the results of four randomised controlled trials
investigating the eﬀects of ipriﬂavone consumption on BMD
and/or bone turnover which have been conducted in post-
menopausal women with either osteopenia or osteoporosis.
One of the papers [60] reviewed two Italian multicentre
studies performed in elderly women with established osteo-
porosis. Elderly women with diagnosis of osteoporosis and
prevalent vertebral fractures were enrolled in seven centres.
A total of 149 subjects entered the two studies, and 111 com-
pleted the 2-year intervention period. In both studies, the
women were randomly allocated to receive either ipriﬂavone
600 mg/day or placebo for two years according to a double-
blind, placebo-controlled, parallel design. In the ﬁrst study,
14 women in the ipriﬂavone group and 13 in the placebo
completed the 2-year treatment. Radial BMD signiﬁcantly
increased at years one (by 4%) and two (by 5%) of the
interventionintheipriﬂavonegroupcomparedwithplacebo.
The urinary hydroxyproline/creatinine ratio decreased sig-
niﬁcantly in the ipriﬂavone group compared to placebo. In
the second study, 41 women in the ipriﬂavone group and
43 in the placebo group completed the 2-year treatment.
Radial BMD signiﬁcantly increased at years one and two
of the intervention in the ipriﬂavone group compared
with placebo. The urinary hydroxyproline/creatinine ratio
decreased signiﬁcantly in the ipriﬂavone group compared
to placebo. The methodological weaknesses of these studies
include small sample size, no intention-to-treat analysis, and
high rate of drop outs in the ﬁrst study, which all limit the
conclusions that can be drawn in relation to the beneﬁts of
ipriﬂavone in preventing the decrease in BMD.
Gennari [55] randomised 56 postmenopausal women
with low vertebral BMD and postmenopausal age less
than ﬁve years to receive either ipriﬂavone (200mg three
times daily) or placebo for two years. All subjects received
also 1,000mg/d of calcium. A statistically signiﬁcant lower
decrease in vertebral BMD was observed in the ipriﬂavone
group compared with placebo at one and two years (−0.4%
and −4.9% in the iproﬂavone and placebo groups at two
years, resp.). At the end of the study, urine hydroxypro-
line/creatinine excretion, a marker of bone resorption,
was signiﬁcantly higher in the placebo group than in the
ipriﬂavone group.
In the study by Ohta et al. [56], 60 women with
postmenopausal osteopenia or osteoporosis were randomly
assigned to receive either 600 mg/d ipriﬂavone or 0.8g/d
calcium lactate for one year. The rate of the decrease
in L2-4 BMD was signiﬁcantly greater in the calcium
lactate group than in the ipriﬂavone group. Median urinary
deoxypyridinoline concentrations signiﬁcantly decreased in
the ipriﬂavone group after one year compared to baseline,6 Journal of Osteoporosis
whereas no changes were observed in the control group.
No statistical comparison between ipriﬂavone and control
groups was reported for this marker of bone resorption.
In a large prospective, randomised, double-blind,
placebo-controlled trial including 474 postmenopausal Cau-
casian women aged 45 to 75 years with osteopenia or
osteoporosis Alexandersen et al. [62] randomly assigned
subjects to receive either ipriﬂavone (200mg 3 times per
day, n = 234) or placebo (n = 240) for three years in
addition to 500mg/d of calcium. Based on an intention-
to-treat analysis, the annual percent change from baseline
in BMD at the lumbar spine or at any of the other sites
measured did not diﬀer signiﬁcantly between the ipriﬂavone
and the placebo groups after 36 months of treatment. The
response of biochemical markers of bone turnover did not
diﬀer between groups. The number of women with new
vertebralfractureswasnotdiﬀerentbetweentheintervention
and control groups after three years of follow-up.
Although four small intervention studies suggest a role
of ipriﬂavone in attenuating the loss of BMD at the
lumbar spine in postmenopausal women by decreasing bone
resorption, the largest RCT with the highest number of
subjects and the longest followup indicates that ipriﬂavone
does not prevent bone loss or aﬀect biochemical markers
of bone turnover in postmenopausal women. Furthermore,
a cause and eﬀect relationship has not been established
between the consumption of ipriﬂavone and maintenance of
bone mineral density in postmenopausal women.
6. Concluding Remarks
Diet and nutrition contribute to the diﬀerent rates of cancer
and other diseases throughout the world. Diets rich in plant-
derived products may supply a variety of phytoestrogens
capable of producing a range of pharmacological eﬀects in
the human body. As people live longer, women are spending
more of their lives in menopause, aﬀected by a variety of
estrogen-related conditions such as osteoporosis, cognitive
decline and cardiovascular diseases.
Soy protein has a modest beneﬁcial eﬀect on bone.
However, after the analyses of existing literature it should
be stated that it is too early to state whether soy protein or
its isoﬂavones can be substituted for estrogen in preventing
the bone loss induced by ovarian hormone deﬁciency. More
studies need to be conducted to ﬁnd out whether: (1)
isoﬂavones independent of soy protein can prevent ovarian
hormone deﬁciency-associated bone loss; (2) consumption
ofsoycontainingfoodorintakeofisoﬂavonesonadailybasis
isnecessarytoobservetheexpectedbeneﬁcialeﬀectsonbone
or simply intermittent use will produce the same results; (3)
the eﬀect of soy protein or its isoﬂavones on bone is transi-
tory; (4) the combination of soy isoﬂavones and lower doses
of estrogens can prevent postmenopausal bone mineral loss
and at the same time lower the estrogen-associated risks. It is
essential that future studies be performed with standardized
and structurally characterized mixtures of compounds or
with isolated phytoestrogens. Also more research is needed
to determine the eﬃcacy of ipriﬂavone in inhibiting the
decrease in BMD and it is too early to recommend it as
supplement for patients with osteoporosis.
References
[1] National Osteoporosis Foundation, Physician’s Guide to Pre-
vention and Treatment of Osteoporosis, National Osteoporosis
Foundation, Washington, DC, USA, 2003.
[2] R. Eastell, “Pathogenesis of postmenopausal osteoporosis,” in
Primer on the Metabolic Bone Diseases and Disorders of Mineral
Metabolism, M. J. Favus, Ed., pp. 314–316, American Society
for Bone and Mineral Research, Washington, DC, USA, 5th
edition, 2003.
[3] D. Marshall, O. Johnell, and H. Wedel, “Meta-analysis of how
well measures of bone mineral density predict occurrence of
osteoporotic fractures,” British Medical Journal, vol. 312, no.
7041, pp. 1254–1259, 1996.
[4] D. Picard, A. Imbach, M. Couturier, R. Lepage, and L.-
G. Ste-Marie, “Longitudinal study of bone density and its
determinants in women in perior early menopause,” Calciﬁed
Tissue International, vol. 67, no. 5, pp. 356–360, 2000.
[5] C. Gennari, D. Agnusdei, G. Crepaldi, et al., “Eﬀect of
ipriﬂavone—a synthetic derivative of natural isoﬂavones—on
bonemasslossintheearlyyearsaftermenopause,”Menopause,
vol. 5, no. 1, pp. 9–15, 1998.
[ 6 ]D .S .L a u d e r d a l e ,S .J .J a c o b s e n ,S .E .F u r n e r ,P .S .L e v y ,J .
A. Brody, and J. Goldberg, “Hip fracture incidence among
elderly Asian-American populations,” American Journal of
Epidemiology, vol. 146, no. 6, pp. 502–509, 1997.
[7] D.Kritz-SilversteinandD.L.Goodman-Gruen,“Usualdietary
isoﬂavone intake, bone mineral density, and bone metabolism
in post-menopausal women,” Journal of Women’s Health and
Gender-Based Medicine, vol. 11, no. 1, pp. 69–78, 2002.
[8] C.Nagata, H. Shimizu, R.Takami, M.Hayashi, N.Takeda, and
K. Yasuda, “Soy product intake and serum isoﬂavonoid and
estradiol concentrations in relation to bone mineral density in
postmenopausal Japanese women,” Osteoporosis International,
vol. 13, no. 3, pp. 200–204, 2002.
[9] M. D. Scheiber, J. H. Liu, M. T. R. Subbiah, R. W. Rebar, and
K. D. R. Setchell, “Dietary inclusion of whole soy foods results
in signiﬁcant reductions in clinical risk factors for osteo-
porosis and cardiovascular disease in normal postmenopausal
women,” Menopause, vol. 8, no. 5, pp. 384–392, 2001.
[10] C. S. Hsu, W. W. Shen, Y. M. Hsueh, et al., “Soy isoﬂavone
supplementation in post-menopausal women. Eﬀects on
plasmalipids,antioxidantenzymeactivitiesandbonedensity,”
Journal of Reproductive Medicine, vol. 46, pp. 221–226, 2001.
[11] K. E. Wangen, A. M. Duncan, B. E. Merz-Demlow, et al.,
“Eﬀects of soy isoﬂavones on markers of bone turnover
in premenopausal and postmenopausal women,” Journal of
Clinical Endocrinology and Metabolism,v o l .8 5 ,n o .9 ,p p .
3043–3048, 2000.
[12] K. D. R. Setchell, “Soy isoﬂavones—beneﬁts and risks from
nature’s selective estrogen receptor modulators (SERMs),”
Journal of the American College of Nutrition, vol. 20, no. 5
supplement, pp. 354S–362S, 2001.
[13] R. A. Dixon and D. Ferreira, “Genistein,” Phytochemistry, vol.
60, no. 3, pp. 205–211, 2002.
[14] H.-J. Wang and P. A. Murphy, “isoﬂavone content in com-
mercial soybean foods,” Journal of Agricultural and Food
Chemistry, vol. 42, no. 8, pp. 1666–1673, 1994.Journal of Osteoporosis 7
[15] H.-J. Wang and P. A. Murphy, “isoﬂavone composition of
American and Japanese soybeans in Iowa: eﬀects of variety,
crop year, and location,” Journal of Agricultural and Food
Chemistry, vol. 42, no. 8, pp. 1674–1677, 1994.
[16] T. Cornwell, W. Cohick, and I. Raskin, “Dietary phytoestro-
gens and health,” Phytochemistry, vol. 65, no. 8, pp. 995–1016,
2004.
[17] M. J. de Kleijn, Y. T. Van der Schouw, P. W. F. Wilson, et al.,
“Intake of dietary phytoestrogens is low in postmenopausal
women in the United States: the framingham study,” Journal
of Nutrition, vol. 131, no. 6, pp. 1826–1832, 2001.
[18] H. Adlercreutz, H. Markkanen, and S. Watanabe, “Plasma
concentrations of phyto-oestrogens in Japanese men,” The
Lancet, vol. 342, no. 8881, pp. 1209–1210, 1993.
[19] S. Zhou, G. Turgeman, S. E. Harris, et al., “Estrogens activate
bone morphogenetic protein-2 gene transcription in mouse
mesenchymal stem cells,” Molecular Endocrinology, vol. 17, no.
1, pp. 56–66, 2003.
[20] S. Nilsson and J.-A. Gustafsson, “Biological role of estrogen
and estrogen receptors,” Critical Reviews in Biochemistry and
Molecular Biology, vol. 37, no. 1, pp. 1–28, 2002.
[21] M. Yamaguchi, “isoﬂavone and bone metabolism: its cellular
mechanismandpreventiveroleinboneloss,”JournalofHealth
Science, vol. 48, no. 3, pp. 209–222, 2002.
[22] A. Brzezinski and A. Debi, “Phytoestrogens: the “natural”
selective estrogen receptor modulators?” European Journal of
Obstetrics Gynecology and Reproductive Biology, vol. 85, no. 1,
pp. 47–51, 1999.
[23] J. M. Riddle and J. W. Estes, “Oral contraceptives in ancient
and medieval times,” American Scientist, vol. 80, pp. 226–233,
1992.
[24] R. J. Miksicek, “Commonly occurring plant ﬂavonoids have
estrogenicactivity,”MolecularPharmacology,vol.44,no.1,pp.
37–43, 1993.
[25] G. G. J. M. Kuiper, J. G. Lemmen, B. Carlsson, et al.,
“Interaction of estrogenic chemicals and phytoestrogens with
estrogenreceptor β,” Endocrinology,vol.139,no.10,pp.4252–
4263, 1998.
[26] D. Wang, J. Gutkowska, M. Marcinkiewicz, G. Rachelska,
and M. Jankowski, “Genistein supplementation stimulates
t h eo x y t o c i ns y s t e mi nt h ea o r t ao fo v a r i e c t o m i z e dr a t s , ”
Cardiovascular Research, vol. 57, no. 1, pp. 186–194, 2003.
[ 2 7 ]S .C .H o ,S .G .C h a n ,Q .Y i ,E .W o n g ,a n dP .C .L e u n g ,“ S o y
intake and the maintenance of peak bone mass in Hong Kong
Chinese women,” Journal of Bone and Mineral Research, vol.
16, no. 7, pp. 1363–1369, 2001.
[ 2 8 ]K .E .W a n g e n ,A .M .D u n c a n ,B .E .M e r z - D e m l o w ,e ta l . ,
“Eﬀects of soy isoﬂavones on markers of bone turnover
in premenopausal and postmenopausal women,” Journal of
Clinical Endocrinology and Metabolism,v o l .8 5 ,n o .9 ,p p .
3043–3048, 2000.
[29] N. Omi, S. Aoi, K. Murata, and I. Ezawa, “Evaluation of the
eﬀect of soybean milk and soybean milk peptide on bone
metabolism in the rat model with ovariectomized osteoporo-
sis.,” Journal of Nutritional Science and Vitaminology, vol. 40,
no. 2, pp. 201–211, 1994.
[30] B. H. Arjmandi, R. Birnbaum, N. V. Goyal, et al., “Bone-
sparing eﬀect of soy protein in ovarian hormone-deﬁcient
rats is related to its isoﬂavone content,” American Journal of
Clinical Nutrition, vol. 68, no. 6, pp. 1364S–1368S, 1998.
[31] B. H. Arjmandi, M. J. Getlinger, N. V. Goyal, et al., “The role
of soy protein with normal or reduced isoﬂavone content in
reversing bone loss induced by ovarian hormone deﬁciency
in rats,” American Journal of Clinical Nutrition,v o l .6 8 ,n o .6 ,
supplement, pp. 1358S–1363S, 1998.
[32] C. Picherit, B. Chanteranne, C. Bennetau-Pelissero, et al.,
“Dose-dependent bone-sparing eﬀects of dietary isoﬂavones
in the ovariectomised rat,” British Journal of Nutrition, vol. 85,
no. 3, pp. 307–316, 2001.
[33] C. Picherit, C. Bennetau-Pelissero, B. Chanteranne, et al.,
“Soybean isoﬂavones dose-dependently reduce bone turnover
but do not reverse established osteopenia in adult ovariec-
tomizedrats,”JournalofNutrition,vol.131,no.3,pp.723–728,
2001.
[34] J. J. B. Anderson, W. W. Ambrose, and S. C. Garner, “Biphasic
eﬀects of genistein on bone tissue in the ovariectomized,
lactatingratmodel,”ProceedingsoftheSocietyforExperimental
Biology and Medicine, vol. 217, no. 3, pp. 345–350, 1998.
[35] P. Fanti, M. C. Monier-Faugere, Z. Geng, et al., “The
phytoestrogen genistein reduces bone loss in short-term
ovariectomized rats,” Osteoporosis International, vol. 8, no. 3,
pp. 274–281, 1998.
[36] C. Picherit, V. Coxam, C. Bennetau-Pelissero, et al., “Daidzein
is more eﬃcient than genistein in preventing ovariectomy-
induced bone loss in rats,” Journal of Nutrition, vol. 130, no.
7, pp. 1675–1681, 2000.
[37] G. A. Greendale, G. FitzGerald, M.-H. Huang, et al., “Dietary
soy isoﬂavones and bone mineral density: results from the
Study of Women’s Health Across the Nation,” American
Journal of Epidemiology, vol. 155, no. 8, pp. 746–754, 2002.
[38] D. L. Alekel, A. S. Germain, C. T. Peterson, K. B. Hanson, J.
W. Stewart, and T. Toda, “isoﬂavone-rich soy protein isolate
attenuates bone loss in the lumbar spine of perimenopausal
women,” American Journal of Clinical Nutrition,v o l .7 2 ,n o .3 ,
pp. 844–852, 2000.
[39] N. Morabito, A. Crisafulli, C. Vergara, et al., “Eﬀects of
genistein and hormone-replacement therapy on bone loss
in early postmenopausal women: a randomized double-
blind placebo-controlled study,” Journal of Bone and Mineral
Research, vol. 17, no. 10, pp. 1904–1912, 2002.
[ 4 0 ]S .M .P o t t e r ,J .A .B a u m ,H .T e n g ,R .J .S t i l l m a n ,N .F .S h a y ,
and J. W. Erdman Jr., “Soy protein and isoﬂavones: their
eﬀects on blood lipids and bone density in postmenopausal
women,” American Journal of Clinical Nutrition,v o l .6 8 ,n o .6 ,
supplement, pp. 1375S–1379S, 1998.
[41] J. Mei, S. S. C. Yeung, and A. W. C. Kung, “High dietary
phytoestrogen intake is associated with higher bone mineral
density in postmenopausal but not premenopausal women,”
Journal of Clinical Endocrinology and Metabolism, vol. 86, no.
11, pp. 5217–5221, 2001.
[ 4 2 ]E .B r i n k ,V .C o x a m ,S .R o b i n s ,K .W a h a l a ,A .C a s s i d y ,a n d
F. Branca, “Long-term consumption of isoﬂavone-enriched
foods does not aﬀect bone mineral density, bone metabolism,
or hormonal status in early postmenopausal women: a ran-
domized, double-blind, placebo controlled study,” American
Journal of Clinical Nutrition, vol. 87, no. 3, pp. 761–770, 2008.
[43] J. Liu, S. C. Ho, Y.-X. Su, W.-Q. Chen, C.-X. Zhang, and Y.-
M. Chen, “Eﬀect of long-term intervention of soy isoﬂavones
on bone mineral density in women: a meta-analysis of
randomized controlled trials,” Bone, vol. 44, no. 5, pp. 948–
953, 2009.
[44] T. Horiuchi, T. Onouchi, M. Takahashi, H. Ito, and H. Orimo,
“Eﬀect of soy protein on bone metabolism in postmenopausal
Japanesewomen,”OsteoporosisInternational,v ol.11,no .8,pp .
721–724, 2000.8 Journal of Osteoporosis
[45] M. D. Scheiber, K. D. R. Setchell, J. H. Liu, et al., “Dietary soy
supplementation reduces LDL-oxidation and bone turnover
in healthy postmenopausal women,” in Proceedings of the
Endocrine Society Meeting, San Diego, Calif, USA, 1999.
[46] B. H. Arjmandi, D. A. Khalil, E. A. Lucas, et al., “Soy protein
with its isoﬂavones improves bone markers in middle-aged
and elderly women,” FASEB Journal, vol. 15, article 728, 2000.
[47] D.-F. Ma, L.-Q. Qin, P.-Y. Wang, and R. Katoh, “Soy isoﬂavone
intakeinhibitsboneresorptionandstimulatesboneformation
in menopausal women: meta-analysis of randomizedcon-
trolled trials,” European Journal of Clinical Nutrition, vol. 62,
no. 2, pp. 155–161, 2008.
[48] E. M. Choi, K. S. Suh, Y. S. Kim, et al., “Soybean ethanol
extractincreasesthefunctionofosteoblasticMC3T3-E1cells,”
Phytochemistry, vol. 56, pp. 733–739, 2001.
[49] A. Atmaca, M. Kleerekoper, M. Bayraktar, and O. Kucuk,
“Soy isoﬂavones in the management of postmenopausal
osteoporosis,” Menopause, vol. 15, no. 4, pp. 748–757, 2008.
[50] E. Romagnoli, S. Minisola, V. Carnevale, et al., “Eﬀect of
estrogen deﬁciency on IGF-I plasma levels: relationship with
bone mineral density in perimenopausal women,” Calciﬁed
Tissue International, vol. 53, no. 1, pp. 1–6, 1993.
[51] M. Nasu, T. Sugimoto, M. Chihara, M. Hiraumi, F. Kurimoto,
and K. Chihara, “Eﬀect of natural menopause on serum
levels of IGF-I and IGF-binding proteins: relationship with
bonemineraldensityandlipidmetabolisminperimenopausal
women,”EuropeanJournalofEndocrinology,vol.136,no.6,pp.
608–616, 1997.
[52] S. Boonen, E. Lesaﬀre, J. Dequeker, et al., “Relationship
between baseline insulin-like growth factor-I (IGF-I) and
femoral bone density in women aged over 70 years: potential
implications for the prevention of age-related bone loss,”
Journal of the American Geriatrics Society, vol. 44, no. 11, pp.
1301–1306, 1996.
[53] D.-F. Ma, L.-Q. Qin, P.-Y. Wang, and R. Katoh, “Soy
isoﬂavoneintakeincreasesbonemineraldensityinthespineof
menopausal women: meta-analysis of randomized controlled
trials,” Clinical Nutrition, vol. 27, no. 1, pp. 57–64, 2008.
[54] M. Gambacciani, A. Spinetti, L. Piaggesi, et al., “Ipriﬂavone
prevents the bone mass reduction in premenopausal women
treated with gonadotropln hormone-releasing hormone ago-
nists,” Bone and Mineral, vol. 26, no. 1, pp. 19–26, 1994.
[55] C. Gennari, “Eﬀect of ipriﬂavone—a synthetic derivative of
natural isoﬂavones—on bone mass loss in the early years after
menopause,” Menopause, vol. 5, no. 1, pp. 9–15, 1998.
[56] H. Ohta, S. Komukai, K. Makita, T. Masuzawa, and S. Nozawa,
“Eﬀects of 1-year ipriﬂavone treatment on lumbar bone min-
eral density and bone metabolic markers in postmenopausal
women with low bone mass,” Hormone Research, vol. 51, no.
4, pp. 178–183, 1999.
[57] L. Pagano, L. Teoﬁli, L. Mele, et al., “Oral ipriﬂavone (7-
isopropoxy-isoﬂavone) treatment for elderly patients with
resistant acute leukemias,” Annals of Oncology, vol. 10, no. 1,
pp. 124–125, 1999.
[58] Y. Sato, H. Kuno, M. Kaji, N. Saruwatari, and K. Oizumi,
“Eﬀect of ipriﬂavone on bone in elderly hemiplegic stroke
patientswithhypovitaminosisD,”AmericanJournalofPhysical
Medicine and Rehabilitation, vol. 78, no. 5, pp. 457–463, 1999.
[59] Y. Somekawa, M. Chiguchi, T. Ishibashi, K. Wakana, and T.
Aso, “Eﬃcacy of ipriﬂavone in preventing adverse eﬀects of
leuprolide,” Journal of Clinical Endocrinology and Metabolism,
vol. 86, no. 7, pp. 3202–3206, 2001.
[60] D. Agnusdei and L. Bufalino, “Eﬃcacy of ipriﬂavone in
establishedosteoporosisandlong-termsafety,”CalciﬁedTissue
International, vol. 61, supplement 1, pp. S23–S27, 1997.
[61] J. Y. Reginster, “Ipriﬂavone multicenter european fracture
study. Ipriﬂavone in the treatment of postmenopausal osteo-
porosis: a randomized controlled trial,” Journal of the Ameri-
can Medical Association, vol. 285, no. 11, pp. 1482–1488, 2001.
[62] P. Alexandersen, A. Toussaint, C. Christiansen, et al., “Ipri-
ﬂavone in the treatment of postmenopausal osteoporosis: a
randomized controlled trial,” Journal of the American Medical
Association, vol. 285, no. 11, pp. 1482–1488, 2001.